Destiny Pharma - INITIATION - Building an Infection Prevention Powerhouse (Sponsored Research, TP £1.20, 44pgs)
Destiny Pharma (DEST) is an LSE-listed Biotech specialising in preventative medicine, with two P3 ready drugs. XF-73 is a novel antibacterial with a rapid and unique onset of action and best-in-class resistance profile, with positive Phase 2b data in preventing post-surgical site infections. NTCD-M3 is a non-pathogenic strain of C. difficile, designed to prevent C. diff infection (CDI) recurrence by crowding out pathogenic forms of the bacteria. With best-in-class P2 data, Sebela acquired the US rights in Feb-23 and will fully fund P3. A 2023 fundraising extended Destiny’s runway to H224, but we expect new deals to extend this further, with a focus on securing a large upfront for the XF-73 out-licensing. With non-risk adj. peak sales of £900m for the 2 drugs, our SOTP values DEST at £1.20/share.For access to the initiation, please contact Naresh Chouhan ( )
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.